BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PRELIMINARY REPORT OF THE ITALIAN TRIAL

被引：0
|
作者：
Tedeschi, A. [1 ]
Coscia, M. [2 ]
Rossi, D. [3 ]
Ricci, F. [1 ]
D'Arena, G. [4 ]
Orlandi, E. [5 ]
Petrizzi, V. Belsito [6 ]
Scarfo, L. [7 ]
Vitale, C. [2 ]
Vismara, E. [1 ]
Gaidano, G. [3 ]
Morra, E. [1 ]
Massaia, M. [2 ]
Montillo, M. [1 ]
机构：
[1] Osped Niguarda Ca Granda, Dpt Hematol, Milan, Italy
[2] Univ Turin, Dpt Hematol, Turin, Italy
[3] Univ Novara, Dpt Hematol, Novara, Italy
[4] IRCCS, Dpt Hematol, San Giovanni Rotondo, Italy
[5] Univ Pavia, Dpt Hematol, I-27100 Pavia, Italy
[6] Nocera Inferiore Hosp, Dpt Internal Med, Nocera Inferiore, Italy
[7] Univ HSR, Dpt Hematol, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：173 / 173
页数：1
相关论文
共 50 条
  • [1] BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PHASE I SAFETY PROFILE RESULTS OF THE ITALIAN TRIAL
    Tedeschi, A.
    Coscia, M.
    Rossi, D.
    Vismara, E.
    Ricci, F.
    Vitale, C.
    Morra, E.
    Gaidano, G.
    Massaia, M.
    Montillo, M.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 324 - 324
  • [2] Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia
    Tedeschi, Alessandra
    Rossi, Davide
    Coscia, Marta
    Vismara, Eleonora
    Petrizzi, Valeria Belsito
    Orlandi, Ester
    Cascavilla, Nicola
    Scarfo, Lydia
    Motta, Marina
    Vitale, Candida
    Ricci, Francesca
    De Paoli, Lorenzo
    D'Arco, Alfonso Maria
    Gallamini, Andrea
    Gaidano, Gianluca
    Morra, Enrica
    Massaia, Massimo
    Montillo, Marco
    [J]. BLOOD, 2012, 120 (21)
  • [3] Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL)
    Hill, Brian T.
    Caimi, Paolo
    Kindwall-Keller, Tammy
    Habecker, Becky
    Kalaycio, Matt
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2014, 164 (02) : 297 - 299
  • [4] A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)
    Nabhan, C
    Patton, D
    Gordon, LI
    Riley, MB
    Kuzel, T
    Tallman, MS
    Rosen, ST
    [J]. LEUKEMIA & LYMPHOMA, 2004, 45 (11) : 2269 - 2273
  • [5] Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients
    Montillo, Marco
    Tedeschi, Alessandra
    Gaidano, Gianluca
    Coscia, Marta
    Petrizzi, Valeria Belsito
    Orlandi, Ester
    Cascavilla, Nicola
    Ghia, Paolo
    Motta, Marina
    Gallamini, Andrea
    Frustaci, Anna Maria
    Rossi, Davide
    De Paoli, Lorenzo
    Nichelatti, Michele
    Morra, Enrica
    Massaia, Massimo
    [J]. HAEMATOLOGICA, 2014, 99 (09) : E159 - E161
  • [6] Phase II Trial to Evaluate the Efficacy and Safety of the Combination of Obinutuzumab and Bendamustine Treatment in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Garcia-Marco, Jose
    Tello, Patricia Baltasar
    Garcia, Esther Gonzalez
    Herranz, Eduardo Rios
    Payer, Angel Ramirez
    Castera, Maria Jose Terol
    Champ, Diana
    Perez, Angeles Medina
    Gironella, Mercedes
    Fernandez, Alicia Rodriguez
    Prat, Ana Muntanola
    Cabrera, Alexia Suarez
    Chacon, Manuel Jurado
    Zarzoso, Miguel Fernandez
    Rodriguez, Mercedes
    Clavel, Juana
    Sahun, Maria Victoria Dourdil
    Coll, Christelle M. Ferra
    Persona, Ernesto Perez
    Santos, Carmen Milagros Marrero
    Fores, Rafael
    Delgado, Julio
    [J]. BLOOD, 2017, 130
  • [7] Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial
    Cortelezzi, A.
    Sciume, M.
    Liberati, A. M.
    Vincenti, D.
    Cuneo, A.
    Reda, G.
    Laurenti, L.
    Zaja, F.
    Marasca, R.
    Chiarenza, A.
    Gritti, G.
    Orsucci, L.
    Storti, S.
    Angelucci, E.
    Cascavilla, N.
    Gobbi, M.
    Mauro, F. R.
    Morabito, F.
    Fabris, S.
    Piciocchi, A.
    Vignetti, M.
    Neri, A.
    Rossi, D.
    Giannarelli, D.
    Guarini, A.
    Foa, R.
    [J]. LEUKEMIA, 2014, 28 (03) : 642 - 648
  • [8] Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial
    A Cortelezzi
    M Sciumè
    A M Liberati
    D Vincenti
    A Cuneo
    G Reda
    L Laurenti
    F Zaja
    R Marasca
    A Chiarenza
    G Gritti
    L Orsucci
    S Storti
    E Angelucci
    N Cascavilla
    M Gobbi
    F R Mauro
    F Morabito
    S Fabris
    A Piciocchi
    M Vignetti
    A Neri
    D Rossi
    D Giannarelli
    A Guarini
    R Foà
    [J]. Leukemia, 2014, 28 : 642 - 648
  • [9] Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study
    Iannitto, Emilio
    Morabito, Fortunato
    Mancuso, Salvatrice
    Gentile, Massimo
    Montanini, Antonella
    Augello, Accursio
    Bongarzoni, Velia
    D'Arco, Alfonso
    Di Renzo, Nicola
    Fazzi, Rita
    Franco, Giovanni
    Marasca, Roberto
    Mule, Antonino
    Musso, Maurizio
    Musto, Pellegrino
    Pennese, Elsa
    Piccin, Andrea
    Rota-Scalabrini, Delia
    Visani, Giuseppe
    Rigacci, Luigi
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 (03) : 351 - 357
  • [10] Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study
    Montillo, Marco
    Tedeschi, Alessandra
    Ricci, Francesca
    Zaccaria, Alfonso
    Crugnola, Monica
    Spriano, Mauro
    Spedini, PierAngelo
    Ilariucci, Fiorella
    Uziel, Lilj
    Attolico, Immacolata
    De Blasio, Angelo
    Vismara, Eleonora
    Morra, Enrica
    Petrizzi, Valeria Belsito
    [J]. BLOOD, 2010, 116 (21) : 595 - 596
12345